Vertex Pharmaceuticals Inc (VRTX) stock saw a modest uptick, ending the day at $422 which represents a slight increase of $5.04 or 1.21% from the prior close of $416.96. The stock opened at $422.73 ...

Vertex Pharmaceuticals Inc (VRTX) stock saw a decline, ending the day at $439.62 which represents a decrease of $-0.11 or -0.03% from the prior close of $439.73. The stock opened at $438.73 and ...

If the drug is approved by the US Food and Drug Administration for the treatment of acute pain in January as expected, the ...

We're kicking off the 43rd Annual Healthcare Conference this morning, and I couldn't be more delighted to introduce Vertex's CEO, Reshma Kewalramani. She's going to come on stage to give a ...

Mumbai: The HSBC Hurun Global Indians List 2024 features 12 women, with Jayshree V. Ullal, Chairperson and CEO of Arista Networks, leading the list at 63. Ullal, whose company is valued at $128 ...

Cebranopadol, a dual-NMR agonist, reached the primary endpoint in a Phase III trial and matched placebo for safety, a ...

In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated ... Democrats, and the Executive) act in unison then, “when you have that kind of come together over ...

MaxCyte Inc. (NASDAQ: MXCT) is a global developer of next-generation cell therapies. They provide crucial technology for cell ...

Evercore ISI analyst Liisa Bayko maintained a Buy rating on Ultragenyx Pharmaceutical (RARE – Research Report) today and set a price target of ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Currently, Vertex Pharmaceuticals is a Zacks Rank #3 (Hold ... Check out the simple yet high-powered approach that Zacks Executive VP Kevin Matras has used to close recent double and triple ...